Most-Read Oncology Articles of 2021
The most-read oncology news of 2021 included the FDA’s review of accelerated approvals, COVID-19 vaccine effectiveness in patients with blood cancer, and more.
Two Approvals in Urothelial Cancer Survive FDA Panel Scrutiny
As hearings of the FDA panel have shown, once a drug is approved and in clinical guidelines, pulling it from the market is not so simple, even if later trials do not confirm phase 2 results.
FDA Update: Merck Action on Keytruda Gastric Cancer Indication Tops Busy Week
Merck will withdraw Keytruda's advanced gastric indication after an FDA panel vote, a drug with supply problems gets a new indication, NDAs for an HIV therapy, and other news.
Antibodies Go Missing After COVID-19 Vaccination in Some Blood Cancer Patients
Lack of antibodies from vaccination mainly affects patients with B cell cancers. Experts say antibodies are just one piece of the puzzle and that other aspects of the immune system fend off serious cases of COVID-19.
Feasibility Study Shows Mobile Devices Help Patients Communicate Cancer Treatment Effects
Mobile devices for patients to report symptoms associated with immune checkpoint inhibitors address an unmet need.
ASCO 2021: Lumakras, First Approved KRAS-targeting Cancer Drug, Looks Promising
The FDA approved Amgen’s Lumakras (sotorasib) last week, the first drug targeting KRAS-mutated cancer to get the agency’s OK. But the clinical and commercial future of the drug is uncertain.
Women Pay More and Get Less from Employer Health Plans
June 19th 2025In a report by JPMorgan Chase's Morgan Health, it was found that 37% of women with employer-sponsored insurance said meeting their deductibles is difficult, and 36% reported that their plans didn’t cover care they expected—or paid less than anticipated.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Lenacapavir HIV PrEP: Not an AIDS Vaccine, but Vaccine Adjacent
June 19th 2025Experts and advocates say that twice-a-year HIV PrEP injections have the prevention potential of a vaccine — and that a once-a-year version of lenacapavir would be even better. But will Yeztugo be available to the people who would benefit most from HIV PrEP?
Read More
